Marc Dunoyer
Chief Executive Officer presso ALEXION PHARMACEUTICALS, INC.
Profilo
Marc Pierre Jean Dunoyer è Chief Financial Officer & Executive Director di AstraZeneca Plc e fa parte del consiglio di amministrazione di altre 5 società. In precedenza ha occupato la posizione di Global Head-Rare Diseases Unit presso GlaxoSmithKline Plc e Presidente di GlaxoSmithKline KK (una filiale di GlaxoSmithKline Plc) e Presidente-Asia Pacific presso Hoechst Marion Roussel SA. Ha ricevuto un MBA da Hautes Etudes Commerciales e una laurea all'Universit de Paris IV Paris-Sorbonne.
Posizioni attive di Marc Dunoyer
Società | Posizione | Inizio |
---|---|---|
ASTRAZENECA PLC | Corporate Officer/Principal | 01/08/2021 |
ALEXION PHARMACEUTICALS, INC. | Chief Executive Officer | - |
Acerta Pharma BV
Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands. | Director/Board Member | - |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Director/Board Member | 07/06/2018 |
Astrazeneca Intermediate Holdings Ltd.
Astrazeneca Intermediate Holdings Ltd. Pharmaceuticals: MajorHealth Technology Part of AstraZeneca PLC, AstraZeneca Intermediate Holdings Ltd. operates as a British intermediate holding company through its subsidiaries and researches, manufactures, and markets pharmaceuticals. The private company is based in Cambridge, UK. | Director/Board Member | - |
AstraZeneca UK Ltd.
AstraZeneca UK Ltd. Miscellaneous Commercial ServicesCommercial Services AstraZeneca UK Ltd. manufactures pharmaceutical products. Its products are used to treat cardiovascular diseases, diabetes, and gastrointestinal infections. The company was founded on November 26, 1998 and is headquartered in London, the United Kingdom. | Director/Board Member | 29/11/2013 |
AstraZeneca KK
AstraZeneca KK Pharmaceuticals: MajorHealth Technology AstraZeneca KK develops, manufactures and sells prescription drugs. It also conducts medical research. The company was founded on April 11, 1975 and is headquartered in Osaka, Japan. | Chairman | - |
Alexion Pharmaceuticals, Inc. /New/ | Chief Executive Officer | 01/08/2021 |
Precedenti posizioni note di Marc Dunoyer
Società | Posizione | Fine |
---|---|---|
ORCHARD THERAPEUTICS PLC | Director/Board Member | 24/01/2024 |
░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░░░░░ ░░ | ░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░ ░░░░░░░░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Formazione di Marc Dunoyer
Hautes Etudes Commerciales | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
ASTRAZENECA PLC | Health Technology |
GSK PLC | Health Technology |
JCR PHARMACEUTICALS CO., LTD. | Health Technology |
Aziende private | 11 |
---|---|
Hoechst Marion Roussel SA | Health Technology |
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
GlaxoSmithKline KK
GlaxoSmithKline KK Household/Personal CareConsumer Non-Durables GlaxoSmithKline KK researches, develops, imports, manufactures and sells toiletry products. The company was founded on August 18, 1928 and is headquartered in Tokyo, Japan | Consumer Non-Durables |
Université de Paris IV Paris-Sorbonne | Consumer Services |
AstraZeneca UK Ltd.
AstraZeneca UK Ltd. Miscellaneous Commercial ServicesCommercial Services AstraZeneca UK Ltd. manufactures pharmaceutical products. Its products are used to treat cardiovascular diseases, diabetes, and gastrointestinal infections. The company was founded on November 26, 1998 and is headquartered in London, the United Kingdom. | Commercial Services |
AstraZeneca KK
AstraZeneca KK Pharmaceuticals: MajorHealth Technology AstraZeneca KK develops, manufactures and sells prescription drugs. It also conducts medical research. The company was founded on April 11, 1975 and is headquartered in Osaka, Japan. | Health Technology |
Astrazeneca Intermediate Holdings Ltd.
Astrazeneca Intermediate Holdings Ltd. Pharmaceuticals: MajorHealth Technology Part of AstraZeneca PLC, AstraZeneca Intermediate Holdings Ltd. operates as a British intermediate holding company through its subsidiaries and researches, manufactures, and markets pharmaceuticals. The private company is based in Cambridge, UK. | Health Technology |
Acerta Pharma BV
Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands. | Health Technology |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Orchard Therapeutics Plc
Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
Alexion Pharmaceuticals, Inc. /New/ |
- Borsa valori
- Insiders
- Marc Dunoyer